Related Experiment Video

Updated: Jun 10, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

85.8K

A comprehensive review of caffeine population pharmacokinetics in preterm infants: Factors affecting clearance

Yaodong He1, Xianhuan Shen2, Jiahao Zhu2

  • 1Department of Pharmacy, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong 518102,China; Department of Clinical Pharmacology, College of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, China.

European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V
|February 6, 2025
PubMed

Insights

Caffeine pharmacokinetics in preterm infants vary due to factors like weight and genetics. Understanding these population pharmacokinetic (PopPK) models is crucial for tailoring caffeine doses for safe and effective apnea treatment.

Area of Science:

  • Pharmacology
  • Neonatal Medicine
  • Pharmacokinetics

Background:

  • Caffeine is FDA-approved for apnea in preterm infants.
  • Preterm infant pharmacokinetics (PK) differ significantly from adults.
  • Population pharmacokinetic (PopPK) models help identify influencing factors.

Purpose of the Study:

  • To review PopPK studies of caffeine in preterm infants.
  • To summarize identified covariates affecting caffeine PK.
  • To inform individualized dosing strategies.

Main Methods:

  • Systematic review of published PopPK studies.
  • Analysis of identified covariates influencing caffeine PK parameters.
  • Evaluation of PK models (1-CMT and 3-CMT).

Main Results:

  • Most studies used a one-compartment model (1-CMT).
  • Covariates like birth weight, genetics, feeding, and illness impact caffeine PK.
  • Genetic polymorphisms and co-medications were significant factors.

Conclusions:

  • Individualized caffeine dosing is essential for preterm infants.
  • Future research should focus on sampling, feeding, and age-related covariates.
  • PopPK data is vital for optimizing neonatal apnea treatment.

Keywords:
CaffeineClearanceIndividualized dosing regimenPopulation pharmacokineticsPreterm infant

More Related Videos

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model08:08

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model

Published on: June 18, 2013

17.3K
Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates05:58

Application of an Amplitude-integrated EEG Monitor Cerebral Function Monitor to Neonates

Published on: September 6, 2017

38.5K

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
Factors Influencing Drug Absorption: Presystemic Elimination01:24

Factors Influencing Drug Absorption: Presystemic Elimination

The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...